MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR)…
HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR)…
Dr. Siddhartha Kadia, CEO of Berkeley Lights “I am honored to lead the talented Berkeley…
REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
ZURICH, Switzerland, March 09, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision…
TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the…
CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech…
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO),…
FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a…
WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage…
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI),…
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical…
Data to be presented at the 2022 annual meeting of American Association for Cancer Research…
On track to complete dosing of the first cohort and share initial data by the…
Broad-acting antihistamine has potential in number of disease areas with unmet clinical need NEW YORK…
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM”…
Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS…
MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical…